MX2022011242A - Inmunomodulación de o-het/aril azálidos. - Google Patents
Inmunomodulación de o-het/aril azálidos.Info
- Publication number
- MX2022011242A MX2022011242A MX2022011242A MX2022011242A MX2022011242A MX 2022011242 A MX2022011242 A MX 2022011242A MX 2022011242 A MX2022011242 A MX 2022011242A MX 2022011242 A MX2022011242 A MX 2022011242A MX 2022011242 A MX2022011242 A MX 2022011242A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- immunomodulating
- formula
- pharmaceutically acceptable
- azalides
- Prior art date
Links
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000026278 immune system disease Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Fodder In General (AREA)
- Saccharide Compounds (AREA)
Abstract
En la presente se definen compuestos inmunomoduladores de la Fórmula (1) estereoisómeros de este y sales farmacéuticamente aceptables de este; en donde R0, R1, R2, R10, W, el anillo C y n son como se define en la presente, estereoisómeros de estos y sales farmacéuticamente aceptables de estos; y composiciones que comprenden dichos compuestos; la invención también incluye métodos para tratar una enfermedad o trastorno inflamatorio y/o inmunológico en un animal al administrar una cantidad terapéuticamente eficaz de un compuesto de la Fórmula (1), estereoisómero de este, y una sal farmacéuticamente aceptable de este; o el uso de dicho compuesto de la Fórmula (1) para preparar un medicamento para tratar una enfermedad o trastorno inflamatorio y/o inmunológico en un animal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062988492P | 2020-03-12 | 2020-03-12 | |
| PCT/US2021/021906 WO2021183762A1 (en) | 2020-03-12 | 2021-03-11 | Immunomodulating o-het-aryl azalides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011242A true MX2022011242A (es) | 2022-12-15 |
Family
ID=75278424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011242A MX2022011242A (es) | 2020-03-12 | 2021-03-11 | Inmunomodulación de o-het/aril azálidos. |
| MX2022011240A MX2022011240A (es) | 2020-03-12 | 2021-03-11 | Azálidos de urea inmunomoduladores. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011240A MX2022011240A (es) | 2020-03-12 | 2021-03-11 | Azálidos de urea inmunomoduladores. |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20230137567A1 (es) |
| EP (2) | EP4118092A1 (es) |
| JP (2) | JP7496427B2 (es) |
| KR (1) | KR20220156570A (es) |
| CN (2) | CN115461353A (es) |
| AR (1) | AR121554A1 (es) |
| AU (2) | AU2021232959B2 (es) |
| BR (2) | BR112022017779A2 (es) |
| CA (2) | CA3175114A1 (es) |
| MX (2) | MX2022011242A (es) |
| TW (2) | TWI830987B (es) |
| WO (4) | WO2021183762A1 (es) |
| ZA (1) | ZA202209530B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4399216A1 (en) | 2021-09-07 | 2024-07-17 | Zoetis Services LLC | Immunomodulating azalides |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1250343E (pt) | 2000-01-27 | 2003-11-28 | Pfizer Prod Inc | Composicoes de antibioticos de azalida |
| ITMI20040124A1 (it) | 2004-01-29 | 2004-04-29 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria |
| US8124744B2 (en) | 2006-05-01 | 2012-02-28 | Taisho Pharmaceutical Co., Ltd. | Macrolide derivatives |
| JP2010535776A (ja) | 2007-08-10 | 2010-11-25 | ワイズセラピューティックス株式会社 | ロキシスロマイシン又はその誘導体の投与による免疫応答の調節 |
| BRPI0908343A2 (pt) | 2008-02-08 | 2020-08-18 | Basilea Pharmaceutica Ag | macrolídeos e seu uso |
| WO2009130189A1 (en) * | 2008-04-23 | 2009-10-29 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | 2'-o,3'-n-bridged macrolides |
| US20130045939A1 (en) | 2010-03-19 | 2013-02-21 | Catabasis Pharmaceuticals, Inc. | Fatty acid macrolide derivatives and their uses |
| CA2869461A1 (en) * | 2012-03-27 | 2013-10-03 | Michael W. BURNET | Anti-inflammatory macrolides |
| WO2014166503A1 (en) | 2013-04-10 | 2014-10-16 | Probiotic Pharmaceuticals Aps | Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect |
| GB201608236D0 (en) * | 2016-05-11 | 2016-06-22 | Fidelta D O O | Seco macrolide compounds |
-
2021
- 2021-03-11 AU AU2021232959A patent/AU2021232959B2/en active Active
- 2021-03-11 AU AU2021233895A patent/AU2021233895A1/en active Pending
- 2021-03-11 CA CA3175114A patent/CA3175114A1/en active Pending
- 2021-03-11 JP JP2022554774A patent/JP7496427B2/ja active Active
- 2021-03-11 AR ARP210100621A patent/AR121554A1/es unknown
- 2021-03-11 EP EP21716891.3A patent/EP4118092A1/en active Pending
- 2021-03-11 US US17/801,328 patent/US20230137567A1/en active Pending
- 2021-03-11 EP EP21715446.7A patent/EP4118091A1/en active Pending
- 2021-03-11 WO PCT/US2021/021906 patent/WO2021183762A1/en unknown
- 2021-03-11 US US17/801,340 patent/US20230136177A1/en active Pending
- 2021-03-11 KR KR1020227035193A patent/KR20220156570A/ko active Search and Examination
- 2021-03-11 TW TW110108700A patent/TWI830987B/zh active
- 2021-03-11 BR BR112022017779A patent/BR112022017779A2/pt unknown
- 2021-03-11 US US17/801,337 patent/US20230129438A1/en active Pending
- 2021-03-11 WO PCT/US2021/021897 patent/WO2021183758A1/en active Application Filing
- 2021-03-11 JP JP2022554776A patent/JP2023517674A/ja active Pending
- 2021-03-11 CN CN202180030710.7A patent/CN115461353A/zh active Pending
- 2021-03-11 WO PCT/US2021/021900 patent/WO2021183759A1/en active Application Filing
- 2021-03-11 CA CA3175087A patent/CA3175087A1/en active Pending
- 2021-03-11 TW TW112148724A patent/TWI847935B/zh active
- 2021-03-11 WO PCT/US2021/021889 patent/WO2021183754A1/en active Application Filing
- 2021-03-11 MX MX2022011242A patent/MX2022011242A/es unknown
- 2021-03-11 US US17/198,863 patent/US11771677B2/en active Active
- 2021-03-11 CN CN202180029670.4A patent/CN115461352A/zh active Pending
- 2021-03-11 MX MX2022011240A patent/MX2022011240A/es unknown
- 2021-03-11 BR BR112022017015A patent/BR112022017015A2/pt unknown
-
2022
- 2022-08-25 ZA ZA2022/09530A patent/ZA202209530B/en unknown
-
2023
- 2023-08-17 US US18/451,243 patent/US20230390237A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022011240A (es) | 2022-12-15 |
| US20230137567A1 (en) | 2023-05-04 |
| WO2021183754A1 (en) | 2021-09-16 |
| TWI830987B (zh) | 2024-02-01 |
| CN115461352A (zh) | 2022-12-09 |
| US11771677B2 (en) | 2023-10-03 |
| TW202200158A (zh) | 2022-01-01 |
| US20230136177A1 (en) | 2023-05-04 |
| EP4118092A1 (en) | 2023-01-18 |
| TW202415385A (zh) | 2024-04-16 |
| AU2021232959A1 (en) | 2022-09-15 |
| KR20220156570A (ko) | 2022-11-25 |
| WO2021183759A1 (en) | 2021-09-16 |
| US20210290591A1 (en) | 2021-09-23 |
| AR121554A1 (es) | 2022-06-15 |
| US20230129438A1 (en) | 2023-04-27 |
| CA3175087A1 (en) | 2021-09-16 |
| JP2023517673A (ja) | 2023-04-26 |
| JP7496427B2 (ja) | 2024-06-06 |
| WO2021183762A1 (en) | 2021-09-16 |
| CA3175114A1 (en) | 2021-09-16 |
| WO2021183758A1 (en) | 2021-09-16 |
| CN115461353A (zh) | 2022-12-09 |
| TWI847935B (zh) | 2024-07-01 |
| JP2023517674A (ja) | 2023-04-26 |
| EP4118091A1 (en) | 2023-01-18 |
| BR112022017015A2 (pt) | 2022-11-16 |
| AU2021233895A1 (en) | 2022-09-29 |
| BR112022017779A2 (pt) | 2022-11-29 |
| ZA202209530B (en) | 2024-02-28 |
| US20230390237A1 (en) | 2023-12-07 |
| AU2021232959B2 (en) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007720A (es) | Lipidos para la administracion de agentes activos en nanoparticulas lipidicas. | |
| MX2021013472A (es) | Moduladores de thr-? y metodos de uso de estos. | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| EP4306523A3 (en) | Imidazoquinoline compounds and uses thereof | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| BR0314126A (pt) | Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio | |
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| RU2007138582A (ru) | Пероральные дозированные формы производных гемцитабина | |
| MX2024000299A (es) | Compuestos antivirales. | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| BR112022009533A2 (pt) | Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica | |
| MX2021011144A (es) | Derivados de las benzodiazepinas como inhibidores del vsr. | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| JOP20190278A1 (ar) | مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية | |
| WO2020251871A3 (en) | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors | |
| MX2024002892A (es) | Azalidos inmunomoduladores. | |
| PH12020551620A1 (en) | Compositions for preventing or treating dry eye | |
| MX2020008230A (es) | Derivados de ester butanoico sustituido con bisfenilo como inhibidores de nep. | |
| MX2023011518A (es) | Compuestos heterocíclicos novedosos y sus usos. |